13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Stand E2/D8 – 2

2017 Edition

Bionext

fr

Did you know: 85% of clinical failures are of biological origin and attributable to secondary targets? Classical in-silico approaches focus on the relationship between a pharmaceutical candidate and its target, but do not consider secondary interactions.
Bionext helps decipher and identifies such secondary targets based on structural knowledge of one of them within any kind of ligand-target (protein, RNA/DNA) interaction. Select the best drug candidates or repurposing possibilities, use BioSigh

Scroll to Top
  • No products in the cart.